Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — August 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #767

    Tror mest på at Gen1046 kan rykke voldsomt. Epco har en hård konkurrent i Roches produkter.

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #768

      Tak alle..En flaske vin knappes op her i Regstrup. Efter udmeldingen af min overtagelse af PI d. 31/7 har vi august 38% flere brugere, 42% nye brugere og 18% flere sidevisninger end samme periode sidste år. Stigningen i forhold til de seneste tre måneder er også markant. Måske et tilfælde. Jeg er dog en glad mand alligevel. 🙂

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #769

        Finanshus løfter kursmålet på Genmab med 26% til 2585. Børsen.

        1 Reply Last reply
        0
        • B Offline
          B Offline
          bibob
          wrote on sidst redigeret af
          #770

          Helge. Så må man håbe der følger lidt flere donationer med. ;-). God weekend til alle. 🙂

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #771

            This will not only be viewed as more convenient by some patients (but not all, note KOLs) but will be cheaper than using Ocrevus, Novartis argues. Whilst Roche’s product has a lower wholesale price of $65,000, Novartis says the total annual cost of Ocrevus rises on average to more than $100,000 when the price of infusions is taken into account.

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #772

              A more subtle difference between Kesimpta and Ocrevus is the former’s shorter half-life and association with faster B-cell repletion, note experts.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #773

                KOLs are quick to acknowledge that Ocrevus is not frequently associated with complications that necessitate rapid B-cell repletion in patients, suggesting that at this is likely to be viewed as a ‘nice to have’ clinical benefit with Kesimpta rather than a meaningful advantage, even if there is some suggestion that B-cell depleting therapies may increase the risk of more severe COVID-19 infection

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #774

                  Just a moment...

                  favicon

                  (www.firstwordpharma.com)

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #775

                    Det er Truist Securities (tidligere Sun Trust) der løfter kursmål til 2585 https://borsen.dk/nyheder/markedsberetninger/finanshus-saetter-genmab-kursmaal-op-med-en-fjerdedel

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #776

                      So they think infusion costs are $35,000??? For basically 2 infusions, admittedly long ones, but
                      that is nuts....

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #777

                        I know wonder what Dara IV estimated costs were, I mean, we knew Dara SC is a cost saver for hospitals, but this is a huge number $$

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #778

                          can't wait for January with a big raise in SC
                          prices 😄

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #779

                            🙂

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #780

                              God søndag morgen. :-).

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #781

                                Lidt om FDA godkendelsen af KdD i RRMM. https://www.onclive.com/view/fda-approves-daratumumab-plus-carfilzomib-dexamethasone-in-relapsed-refractory-myeloma?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #782

                                  Godmorgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #783

                                    bibob..Jeg håber det er lørdag. 🙂

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bibob
                                      wrote on sidst redigeret af
                                      #784

                                      Selvfølgelig Helge. :-D. Det er ikke fordi jeg har en " bagskid " på. Bare en fejl 40. 😉

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #785

                                        Shares of Genmab A/S (NASDAQ:GMAB) reached a new 52-week high on Friday after HC Wainwright raised their price target on the stock from $40.00 to $41.00. HC Wainwright currently has a buy rating on the stock. Genmab A/S traded as high as $38.31 and last traded at $38.31, with a volume of 9217 shares traded. The stock had previously closed at $37.35.

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #786

                                          🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger